MWP
RARE icon

Meriwether Wealth & Planning’s Ultragenyx Pharmaceutical RARE Stock Holding History

Meriwether Wealth & Planning’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$947 Buy
+63
New +$1.51K ﹤0.01% 732

Other funds holding RARE

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Meriwether Wealth & Planning's RARE Position: Q3 2026 in Review

Meriwether Wealth & Planning opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2026: 63 shares worth $947. The stake represents ﹤0.01% of the portfolio and ranks #732 among its holdings.

8 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Meriwether Wealth & Planning held 63 shares of Ultragenyx Pharmaceutical worth $947 as of Q3 2026.
  • Ultragenyx Pharmaceutical was a new Meriwether Wealth & Planning position in Q3 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Meriwether Wealth & Planning's portfolio in Q3 2026, its #732 holding.
  • 8 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Meriwether Wealth & Planning's 13F filing for Q3 2026, filed 13 Oct 2026.